Dr Schwarz’s work has been focused on translational and clinical imaging, both MRI and PET, across a range of Psychiatric and Neurologic disorders. He has been an active participant in many precompetitive consortia, including ADNI, PPMI, several C-Path consortia, IMI-NEWMEDS and IMI-EPAD. He interacts widely with academic groups and specialist imaging vendors to further the science and art of imaging as a tool to better understand disease and enhance drug development.